Projecting Introduction Timelines for Cholera Conjugate Vaccine and Typhoid-Cholera Conjugate Combo Vaccine: A Scenario-Based Forecasting Approach
Objective: This study aimed to project introduction timing and pathways of cholera conjugate vaccine (CCV) and combined typhoid-cholera conjugate vaccines (TCV/CCVs) in 39 low- and middle-income countries and to assess potential barriers to their routine immunization integration. Methods: Accelerated failure time models were fitted using oral cholera vaccine (OCV) introduction as a proxy for CCV adoption. Country-level estimates were standardized using observed post-WHO-prequalification introduction intervals for analogous vaccine transitions. TCV/CCV introduction timing and pathways were projected by combining standardized CCV estimates with a TCV introduction priority index based on typhoid burden and previous vaccination experience. Potential barriers to routine immunization integration were assessed using semi-quantitative scoring approach. Results: Gavi, the Vaccine Alliance (Gavi) eligibility, greater previous OCV experience, and higher cholera intensity were associated with earlier introduction times. After standardization, the median projected time to CCV introduction was 6.9 years after WHO prequalification, with 12 countries introducing within five years. The TCV/CCV projections comprised three pathways: CCV introduction followed by transition to TCV/CCV, direct TCV/CCV introduction and continued CCV use without TCV/CCV introduction during the analysis period. Projected introduction timing was not consistently aligned with routine integration barrier levels for either vaccine. Conclusions: These scenario-based projections provide an early indication of where and when demand may emerge and which countries may require additional programmatic or financing support. The findings can inform demand forecasting, market assessment, manufacturing and supply planning, investment decisions, and introduction preparedness, but the projections should be recalibrated as product-specific evidence becomes available.
Authors
- Victor Raynaud
- Wongyeong Choi (ORCID: https://orcid.org/0000-0002-1463-1597)
- Yunjin Yum (ORCID: https://orcid.org/0000-0003-3070-3615)
- Julia A. Lynch (ORCID: https://orcid.org/0000-0001-8048-5340)
- Jung-Seok Lee (ORCID: https://orcid.org/0000-0002-1038-8948)
- Yongha Hwang (ORCID: https://orcid.org/0000-0001-7903-5000)
Institutions
- International Vaccine Institute (KR)
- Gavi (CH)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-12
- DOI
- https://doi.org/10.64898/2026.11.09.26367688
- Primary Topic
- Vibrio bacteria research studies
- Type
- preprint